The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Catechol‐O‐methyltransferase and Its Inhibitors in Parkinson's Disease
Open accessAbstract
Parkinson's disease (PD) is a neurological disorder characterized by the degeneration of dopaminergic neurons, with consequent reduction in striatal dopamine levels leading to characteristic motor symptoms. The most effective treatment for this disease continues to be the dopamine replacement therapy with levodopa together with an inhibitor of aromatic amino acid decarboxylase (AADC). The efficacy of this therapy, however, decreases with time and most patients develop fluctuating responses and dyskinesias. The last decade showed that the use of catechol‐O‐methyltransferase inhibitors as adjuvants to the levodopa/AADC inhibitor therapy, significantly improves the clinical benefits of this therapy. The purpose of this article is to review the current knowledge on the enzyme catechol‐O‐methyltransferase (COMT) and the role of COMT inhibitors in PD as a new therapeutic approach to PD involving conversion of levodopa to dopamine at the target region in the brain and facilitation of the continuous action of this amine at the receptor sites. A historical overview of the discovery and development of COMT inhibitors is presented with a special emphasis on nebicapone, presently under clinical development, as well as entacapone and tolcapone, which are already approved as adjuncts in the therapy of PD. This article reviews human pharmacokinetic and pharmacodynamic properties of these drugs as well as their clinical efficacy and safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lachman, H. M., Papolos, D. F., Saito, T., Yu, Y.-M., Szumlanski, C. L., & Weinshilboum, R. M. (1996) · Pharmacogenetics · doi:10.1097/00008571-199606000-00007 · Cited by 1,788 · cited 1×
“The Met108/158 variant is associated with low enzymatic activity and decreased thermal stability, while the Val108/158 is associated with high activity (Lachman et al. 1996; Lotta et al. 1995).”
BackgroundChen, J., Lipska, B. K., Halim, N., Ma, Q. D., Matsumoto, M., Melhem, S., Kolachana, B. S., Hyde, T. M., Herman, M. M., Apud, J., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/425589 · Cited by 1,675
Enzymatic O-methylation of epinephrine and other catechols
Axelrod, J., & Tomchick, R. (1958) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64731-3 · Cited by 1,283 · cited 3×
“Catechol-O-methyltransferase (COMT; EC 2.1.1.6), first described by Axelrod and Tomchick (1958), is a magnesium-dependent enzyme that catalyzes the methylation of catechol substrates using S-adenosyl-L-methionine (SAM) as a methyl donor and yielding, as reaction products, the O-methylated catechol…”
BackgroundInfluentialBilder, R. M., Volavka, J., Lachman, H. M., & Grace, A. A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300542 · Cited by 769
TENHUNEN, J., SALMINEN, M., LUNDSTRÖM, K., KIVILUOTO, T., SAVOLAINEN, R., & ULMANEN, I. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.tb19083.x · Cited by 331 · cited 5×
“In most human and rat tissues the levels of S-COMT greatly exceed the levels of MB-COMT, except for the human brain, where it represents about 30% of the total COMT (Karhunen et al. 1994; CNS Drug Reviews, Vol. 13, No. 3, 2007 COMT INHIBITORS 355 Tenhunen et al. 1994).”
BackgroundInfluentialEgan, M., Goldman, D., & Weinberger, D. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.12 · Cited by 20 · cited 1×
“COMT has also been suggested to play a relevant role in modulating prefrontal dopamine neurotransmission (Akil et al. 2003; Bilder et al. 2004; Egan et al. 2002; Huotari et al. 2002).”
Background
Cited by
Adibhatla, R. M., & Hatcher, J. F. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2668 · Cited by 480
Altered Lipid Metabolism in Brain Injury and Disorders
Adibhatla, R. M., & Hatcher, J. F. (2008) · Subcellular Biochemistry · doi:10.1007/978-1-4020-8831-5_9 · Cited by 401
Levodopa in Parkinson’s Disease: Current Status and Future Developments
Tambasco, N., Romoli, M., & Calabresi, P. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170510143821 · Cited by 282
Targeting Metalloenzymes for Therapeutic Intervention
Chen, A. Y., Adamek, R. N., Dick, B. L., Credille, C. V., Morrison, C. N., & Cohen, S. M. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00201 · Cited by 270
Weis, S., Schwiertz, A., Unger, M. M., Becker, A., Faßbender, K., Ratering, S., Kohl, M., Schnell, S., Schäfer, K.-H., & Egert, M. (2019) · npj Parkinson s Disease · doi:10.1038/s41531-019-0100-x · Cited by 145
Metadata
- Authors
- Bonifácio, M. J., Palma, P. N., Almeida, L., & Soares‐da‐Silva, P.
- Venue
- CNS Drug Reviews
- Publisher
- Wiley
- Published
- 2007-09
- Volume
- 13
- Issue
- 3
- Pages
- 352-379
- ISSN
- 1080-563X (ISSN-L)
- 1527-3458
- OpenAlex
- W2146977154
- Cited by
- 199
- References
- 6
- FWCI
- 5.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Catechol‐O‐methyltransferase and Its Inhibitors in Parkinson's Disease. https://app.cochat.ai/papers/10.1111/j.1527-3458.2007.00020.x
- The paper
- Bonifácio, M. J., Palma, P. N., Almeida, L., & Soares‐da‐Silva, P. (2007). Catechol‐O‐methyltransferase and Its Inhibitors in Parkinson's Disease. CNS Drug Reviews. https://doi.org/10.1111/j.1527-3458.2007.00020.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.